Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 6/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 4/20 | 0.46 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18908933 | 0.92 | ACHE (0.45) | ALDH1A1TSHRACHEHRH3BCHE | |
| SCHEMBL18908857 | 0.88 | ALDH1A1 (0.43) | ALDH1A1TSHRACHEHRH3BCHE | |
| SCHEMBL19075549 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TSHRACHEBCHEBACE1 | |
| SCHEMBL18908950 | 0.86 | ACHE (0.46) | ALDH1A1TSHRACHEBCHEBACE1 | |
| SCHEMBL19084054 | 0.86 | ACHE (0.45) | ALDH1A1TSHRACHEHRH3BCHE | |
| SCHEMBL25531028 | 0.84 | ACHE (0.43) | ALDH1A1TSHRACHEHRH3BCHE | |
| SCHEMBL15591085 | 0.83 | ALDH1A1 (0.68) | ALDH1A1TSHRACHEHRH3BCHE | |
| SCHEMBL18908952 | 0.82 | ACHE (0.62) | ALDH1A1ACHEHRH3HTR7L3MBTL1 | |
| SCHEMBL19083894 | 0.81 | ACHE (0.50) | ALDH1A1ACHEHRH3BCHEBACE1 | |
| SCHEMBL23762530 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TSHRACHEBCHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ALDH1A1 1155/4885TSHR 475/4885ACHE 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.